Structure Therapeutics Inc.

Structure Therapeutics Inc. is a clinical-stage biopharmaceutical company developing oral small-molecule medicines for chronic diseases with unmet medical need. Its research platform focuses on structure-based drug discovery and computational chemistry to design therapies against G-protein coupled receptors, with programs centered on metabolic, cardiovascular, and pulmonary diseases.

24.81

24.81

— Structure Therapeutics Inc.
%
Lead clinical candidate0% Aleniglipron and related GLP-1 receptor agonist development for obesity and overweight.
Metabolic pipeline0% Oral small-molecule programs targeting obesity, weight loss, and related metabolic disease.
Pulmonary pipeline0% Product candidates aimed at idiopathic pulmonary fibrosis and other pulmonary diseases.
Discovery platform100% Structure-based drug discovery and computational chemistry used to identify GPCR therapies.

Structure Therapeutics does not sell commercial products today; its direct counterparties are clinical research...

  • Patients with obesity and overweightprimary

    Future end users of aleniglipron and related GLP-1R therapies, seeking oral treatment options for chronic weight management.

  • Patients with metabolic diseaseprimary

    Potential users of next-generation metabolic franchise programs, including GLP-1R and amylin-based therapies.

  • Patients with pulmonary diseasesecondary

    Future users of programs such as LTSE-2578 for idiopathic pulmonary fibrosis and related indications.

  • Clinical and manufacturing partnersprimary

    CROs, CMOs, and suppliers that support discovery, clinical development, and drug supply.

  • Payors and health systemsprimary

    Coverage and reimbursement decision-makers that determine access and commercial uptake after approval.

Structure Therapeutics is incorporated in the Cayman Islands and operates as a global biopharmaceutical company with...

  • •Cayman Islands incorporated holding company
  • •Primary development and regulatory focus in the United States
  • •Clinical programs intended for major global pharmaceutical markets
  • •Third-party manufacturing and supply chain are internationally sourced
  • •No product revenue or country revenue disclosure available

The company is focused on advancing aleniglipron into late-stage development and building a broader oral metabolic...

01
Advance aleniglipron into late-stage developmentshort-term

The lead GLP-1R program is the most advanced asset and the main value driver.

02
Build a next-generation metabolic franchisemedium-term

A broader portfolio can reduce single-asset dependence and expand the addressable market.

03
Expand discovery capabilities and pipeline depthmedium-term

The platform is intended to generate additional oral small-molecule GPCR candidates.

04
Secure external funding and partnershipsshort-term

Clinical development and future commercialization require substantial capital and execution support.

Structure Therapeutics faces the typical risks of a clinical-stage biotech company: uncertain clinical success,...

critical

Clinical development failure

The lead and pipeline assets are still in clinical or preclinical development, so outcomes remain uncertain.

Scope
Aleniglipron, ACCG-2671, ANPA-0073, LTSE-2578
Materiality
high
high

Capital requirements and dilution

The company expects to need substantial additional capital to fund Phase 3 and ongoing operations.

Scope
Equity financing, grants, debt, collaborations
Materiality
high
high

Manufacturing and supply chain dependence

The company relies on third parties, including WuXi STA, for APIs and drug product.

Scope
Clinical and future commercial supply
Materiality
high
high

Reimbursement and market access

Future demand will depend on coverage, pricing, and reimbursement decisions by payors.

Scope
Obesity and chronic disease commercialization
Materiality
high
high

Intellectual property and competition

Competing therapies and patent challenges could reduce the value of the platform and candidates.

Scope
GPCR drug discovery and oral obesity therapies
Materiality
high
Accrued research and development expenses
Can materially change quarterly loss and accrued liabilities
Lease accounting
Affects balance sheet obligations and liquidity planning
Fair value of cash equivalents and short-term investments
Affects reported cash resources and interest income
No revenue recognition yet
Financial statements are driven by R&D and G&A expense timing

Turn Therapeutics Inc.

TTRX · Pharmaceutical Preparations

INTENSITY THERAPEUTICS, INC.

INTS · Biological Products, (No Diagnostic Substances)

TG THERAPEUTICS, INC.

TGTX · Pharmaceutical Preparations

STRATA Skin Sciences, Inc.

SSKN · Surgical & Medical Instruments & Apparatus

Inhibitor Therapeutics, Inc.

INTI · Pharmaceutical Preparations

Century Therapeutics, Inc.

IPSC · Biological Products, (No Diagnostic Substances)

: 29.4.2026